What is a stock summary page? Click here for an overview.
Business Description
Neuronetics Inc
NAICS : 621511
SIC : 8099
ISIN : US64131A1051
Description
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.23 | |||||
| Equity-to-Asset | 0.21 | |||||
| Debt-to-Equity | 2.93 | |||||
| Debt-to-EBITDA | -2.44 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -3.03 | |||||
| Beneish M-Score | -1.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.9 | |||||
| 3-Year EBITDA Growth Rate | -0.6 | |||||
| 3-Year EPS without NRI Growth Rate | -0.3 | |||||
| 3-Year FCF Growth Rate | 4.8 | |||||
| 3-Year Book Growth Rate | -46 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 57.35 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 32.04 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.39 | |||||
| 9-Day RSI | 36.6 | |||||
| 14-Day RSI | 44.6 | |||||
| 3-1 Month Momentum % | 226.06 | |||||
| 6-1 Month Momentum % | 493.59 | |||||
| 12-1 Month Momentum % | -2.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.85 | |||||
| Quick Ratio | 1.71 | |||||
| Cash Ratio | 0.59 | |||||
| Days Inventory | 106.13 | |||||
| Days Sales Outstanding | 88.32 | |||||
| Days Payable | 92.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28.3 | |||||
| Shareholder Yield % | -6.92 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.32 | |||||
| Operating Margin % | -45.46 | |||||
| Net Margin % | -57.69 | |||||
| FCF Margin % | -43.35 | |||||
| ROE % | -181.8 | |||||
| ROA % | -41.22 | |||||
| ROIC % | -63.16 | |||||
| 3-Year ROIIC % | -12.31 | |||||
| ROC (Joel Greenblatt) % | -148.59 | |||||
| ROCE % | -43.58 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.73 | |||||
| PB Ratio | 8.05 | |||||
| EV-to-EBIT | -9.56 | |||||
| EV-to-Forward-EBIT | -45.12 | |||||
| EV-to-EBITDA | -10.14 | |||||
| EV-to-Revenue | 4.59 | |||||
| EV-to-Forward-Revenue | 2.4 | |||||
| EV-to-FCF | -10.58 | |||||
| Price-to-GF-Value | 1.29 | |||||
| Earnings Yield (Greenblatt) % | -10.46 | |||||
| FCF Yield % | -12.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:STIM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Neuronetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 74.89 | ||
| EPS (TTM) ($) | -1.37 | ||
| Beta | 1.16 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1.16 | ||
| Volatility % | 156.56 | ||
| 14-Day RSI | 44.6 | ||
| 14-Day ATR ($) | 0.481338 | ||
| 20-Day SMA ($) | 4.683 | ||
| 12-1 Month Momentum % | -2.73 | ||
| 52-Week Range ($) | 0.52 - 5.92 | ||
| Shares Outstanding (Mil) | 63.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neuronetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neuronetics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neuronetics Inc Frequently Asked Questions
What is Neuronetics Inc(STIM)'s stock price today?
The current price of STIM is $4.08. The 52 week high of STIM is $5.92 and 52 week low is $0.52.
When is next earnings date of Neuronetics Inc(STIM)?
The next earnings date of Neuronetics Inc(STIM) is 2025-05-07 Est..
Does Neuronetics Inc(STIM) pay dividends? If so, how much?
Neuronetics Inc(STIM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers